Elevance Health expands cancer test coverage, shares in S&P 500 spotlight

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 17:52.

Elevance Health (US2855211023) is adding a new oncology diagnostic benefit across its health plans. A nationwide agreement with Plus Therapeutics’ CNSide Diagnostics unit will extend coverage of the CNSide cerebrospinal fluid tumor cell assay to around 45.4 million members, according to a recent press statement cited by Investing.com and effective May 1, 2026, with Elevance Health shares listed on the NYSE and included in the S&P 500 index. Investing.com summary of the CNSide agreement

New agreement on CNSide cancer assay

The coverage arrangement is with CNSide Diagnostics, a division of Houston-based Plus Therapeutics, and applies nationwide to Elevance Health’s commercial and government business, according to the press information referenced by Investing.com. Investing.com company news on Plus Therapeutics The CNSide cerebrospinal fluid tumor cell enumeration assay is used for patients with cancers involving the central nervous system.

The deal lifts contracted coverage of the CNSide assay to about 126 million individuals across U.S. health plans, the Plus Therapeutics release notes, with Elevance Health accounting for roughly one third of that total through its 45.4 million covered lives. Plus Therapeutics press release overview The agreement took effect on May 1, 2026, and is expected to support access to more granular tumor cell monitoring in cerebrospinal fluid.

Digital platform investments complement oncology push

Alongside expanded diagnostic coverage, Elevance Health is reinforcing its digital infrastructure. Research house Zacks recently highlighted enhancements to Elevance’s Health OS data platform, designed to streamline clinical reviews and utilization management by connecting electronic health records, laboratory systems and health information exchanges. Zacks analysis on Elevance Health OS platform The aim is to reduce administrative burden and accelerate clinical decision-making for providers working with Elevance Health plans.

Zacks assigns Elevance Health a Rank #2 (Buy), citing its focus on digital tools and integrated care as supportive factors for the business model. Zacks rating page for ELV Over the past 12 months, Elevance Health shares have modestly outperformed the managed care industry in that analysis universe, reflecting what analysts describe as consistent execution in its core health benefits segment.

How Elevance Health earns its money

Elevance Health generates the bulk of its revenue from managed care premiums in its health benefits business, where it operates affiliated health plans under the Anthem Blue Cross and Blue Shield brands in multiple U.S. states, as well as government programs such as Medicare Advantage and Medicaid managed care. Elevance Health company overview In addition, the Carelon segment bundles pharmacy benefit management, behavioral health, and other services targeting employers, health plans and government customers.

Where the shares trade today

The Elevance Health shares (US2855211023) trade on the NYSE under the ticker ELV at around 515 US dollars as of 2026-06-25, 15:30, based on recent exchange data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. All data are based on sources considered reliable, but their accuracy cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser.